New hope for brain cancer? drug shows promise in early trial

NCT ID NCT02981940

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial involves 45 participants and is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abemaciclib (a targeted cancer drug taken as a capsule)
What this could lead to: If successful, this could point toward a new treatment option for recurrent glioblastoma, a type of brain cancer that is hard to treat.
What could go wrong: This is a small, early-phase trial (45 participants) and results may not apply to all patients. The drug may not effectively control tumor growth or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, WHO GRADE 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 4 brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States
UT, M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94143-0372, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.